Literature DB >> 23461134

Mucosal healing in ulcerative colitis: pathophysiology and pharmacology.

Jakob Benedict Seidelin1, Mehmet Coskun, Ole Haagen Nielsen.   

Abstract

Ulcerative colitis (UC) is a colonic inflammatory condition with a substantial impact on the quality of life of affected persons. The disease carries a cumulative risk of need of colectomy of 20-30% and an estimated cumulative risk of colorectal cancer of 18% after 30 years of disease duration. With the introduction of the tumor necrosis factor-alpha inhibitors for the treatment of UC, it has become increasingly evident that the disease course is influenced by whether or not the patient achieves mucosal healing. Thus, patients with mucosal healing have fewer flare-ups, a decreased risk of colectomy, and a lower probability of developing colorectal cancer. Understanding the mechanisms of mucosal wound formation and wound healing in UC, and how they are affected therapeutically is therefore of importance for obtaining efficient treatment strategies holding the potential of changing the disease course of UC. This review is focused on the pathophysiological mechanism of mucosal wound formation in UC as well as the known mechanisms of intestinal wound healing. Regarding the latter topic, pathways of both wound healing intrinsic to epithelial cells and the wound-healing mechanisms involving interaction between epithelial cells and other cells of the mucosa are discussed. The biochemistry of wound healing in UC provides the basis for the subsequent description of how these pathways are affected by the current medications, and what can be learnt on how to design future treatment regimens for UC based on targeting mucosal healing.

Entities:  

Mesh:

Year:  2013        PMID: 23461134     DOI: 10.1016/b978-0-12-405211-6.00004-8

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  9 in total

1.  Angiopoietin and vascular endothelial growth factor expression in colorectal disease models.

Authors:  Wei-Xin Liu; Shou-Zhi Gu; Shen Zhang; Yi Ren; Li-Xuan Sang; Cong Dai
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis.

Authors:  Moein Eskandari; Fereshteh Asgharzadeh; Mohammad Mostafa Askarnia-Faal; Hamideh Naimi; Amir Avan; Mitra Ahadi; Hassan Vossoughinia; Masoumeh Gharib; Atena Soleimani; Niloufar Naghibzadeh; Gordon Ferns; Mikhail Ryzhikov; Majid Khazaei; Seyed Mahdi Hassanian
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

3.  Evidence against a systemic arterial defect in patients with inflammatory bowel disease.

Authors:  Luke A Neill; Christine M Saundry; Neil H Hyman; George C Wellman
Journal:  J Surg Res       Date:  2014-04-16       Impact factor: 2.192

Review 4.  Intestinal epithelium in inflammatory bowel disease.

Authors:  Mehmet Coskun
Journal:  Front Med (Lausanne)       Date:  2014-08-25

5.  Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment.

Authors:  Regina M Krohn; Sean A Parsons; Jakub Fichna; Kamala D Patel; Robin M Yates; Keith A Sharkey; Martin A Storr
Journal:  J Inflamm (Lond)       Date:  2016-07-14       Impact factor: 4.981

6.  Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis.

Authors:  Christoffer Soendergaard; Peter Helding Kvist; Peter Thygesen; Mats Reslow; Ole Haagen Nielsen; John Joseph Kopchick; Thomas Lindebo Holm
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

7.  Small molecule FAK activator promotes human intestinal epithelial monolayer wound closure and mouse ulcer healing.

Authors:  Qinggang Wang; Shyam K More; Emilie E Vomhof-DeKrey; Mikhail Y Golovko; Marc D Basson
Journal:  Sci Rep       Date:  2019-10-11       Impact factor: 4.379

8.  Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease.

Authors:  Cecilia Jädert; Mia Phillipson; Lena Holm; Jon O Lundberg; Sara Borniquel
Journal:  Redox Biol       Date:  2013-12-24       Impact factor: 11.799

9.  Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression.

Authors:  Xu Zhang; Qing-Hua Deng; Jian-Hua Deng; Sheng-Ju Wang; Qiu Chen
Journal:  Korean J Physiol Pharmacol       Date:  2020-02-20       Impact factor: 2.016

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.